e-Therapeutics plc Director/PDMR Shareholding (6882O)
August 22 2017 - 8:13AM
UK Regulatory
TIDMETX
RNS Number : 6882O
e-Therapeutics plc
22 August 2017
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY
PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Oxford, UK, 22 August 2017 - e-therapeutics plc (AIM: ETX), the
computer-based drug discovery platform company, announces that it
has received notifications from two of its directors that they have
purchased, in aggregate, 520,000 shares in the Company at a price
of 10.6 pence per share. The purchases took place today.
The number of ordinary shares purchased by each director is set
out below:
Director Number
of shares
purchased
------------ -----------
Iain Ross 250,000
------------ -----------
Ray Barlow 270,000
------------ -----------
Mr Ross purchased the shares through his self-invested personal
pension (SIPP) and, following these trades, the beneficial
interests of those directors in ordinary shares of ETX are as
follows:
Director Number Percentage
of shares of issued
held share
capital
------------ ----------- -----------
Iain Ross 1,250,000 0.47%
------------ ----------- -----------
Ray Barlow 1,100,000 0.41%
------------ ----------- -----------
The notifications below, made in accordance with the
requirements of the EU Market Abuse Regulation, provide further
details:
1 Details of the person discharging managerial
responsibilities/person closely associated
--- -------------------------------------------------------------------
a) Name Iain Ross
--- ------------------------ -----------------------------------------
2 Reason for the notification
--- -------------------------------------------------------------------
a) Position/status Non-Executive Chairman
--- ------------------------ -----------------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ -----------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------------
a) Name e-therapeutics plc
--- ------------------------ -----------------------------------------
b) LEI 21380049RHSSJXWKYT18
--- ------------------------ -----------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- -------------------------------------------------------------------
a) Description of Ordinary shares of 0.1 pence
the financial
instrument, type ISIN: GB00B2823H99
of instrument
Identification
code
--- ------------------------ -----------------------------------------
b) Nature of the Purchase of shares through self-invested
transaction personal pension (SIPP)
--- ------------------------ -----------------------------------------
c) Price(s) and 250,000 ordinary shares at a price
volume(s) of 10.6 pence per share
--- ------------------------ -----------------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ -----------------------------------------
e) Date of the transaction 22 August 2017
--- ------------------------ -----------------------------------------
f) Place of the London Stock Exchange, AIM (XLON)
transaction
--- ------------------------ -----------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
--- -------------------------------------------------------------
a) Name Ray Barlow
--- ------------------------ -----------------------------------
2 Reason for the notification
--- -------------------------------------------------------------
a) Position/status Chief Executive Officer
--- ------------------------ -----------------------------------
b) Initial notification/ Initial notification
Amendment
--- ------------------------ -----------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
--- -------------------------------------------------------------
a) Name e-therapeutics plc
--- ------------------------ -----------------------------------
b) LEI 21380049RHSSJXWKYT18
--- ------------------------ -----------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
--- -------------------------------------------------------------
a) Description of Ordinary shares of 0.1 pence
the financial
instrument, type ISIN: GB00B2823H99
of instrument
Identification
code
--- ------------------------ -----------------------------------
b) Nature of the Purchase of shares
transaction
--- ------------------------ -----------------------------------
c) Price(s) and 270,000 ordinary shares at a price
volume(s) of 10.6 pence per share
--- ------------------------ -----------------------------------
d) Aggregated information N/A
- Aggregated
volume
- Price
--- ------------------------ -----------------------------------
e) Date of the transaction 22 August 2017
--- ------------------------ -----------------------------------
f) Place of the London Stock Exchange, AIM (XLON)
transaction
--- ------------------------ -----------------------------------
For further information, please contact:
e-therapeutics plc Tel: +44 (0) 1993
Ray Barlow, Chief Executive 883 125
Officer www.etherapeutics.co.uk
Steve Medlicott, Finance
Director
Numis Securities Limited Tel: +44 (0) 207
Michael Meade/Freddie Barnfield 260 1000
(Corporate Finance) www.numis.com
James Black (Corporate
Broking)
Instinctif Partners Tel: +44 (0) 207
Melanie Toyne Sewell/Alex 457 2020
Shaw Email: e-therapeutics@instinctif.com
About e-therapeutics plc
We are an Oxford-based company with a unique and powerful
computer-based drug discovery platform and a specialised approach
to network biology.
Our novel methodology and our Discovery Engine allow us to
discover new and better drugs in a more efficient and effective
way.
e-therapeutics is headquartered in Oxford. For more information
about the Company please visit www.etherapeutics.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFLVTFIFFID
(END) Dow Jones Newswires
August 22, 2017 09:13 ET (13:13 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024